Examining Neurocrine Biosciences Valuation After 24% Stock Surge and Pipeline Progress in 2025 [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
Plenty of investors are weighing whether the company's trajectory and valuation line up for a smart buy, a confident hold, or a timely sell. Over the past year, the stock has moved steadily higher, up 24.1%. Even in the last week, shares gained 2.8%, signaling a bump in sentiment. That positive momentum stands in contrast to some short-term turbulence, such as last month's modest dip of 1.8%. The story behind these moves is not just about numbers. Recent updates from Neurocrine's expanding pharmaceutical pipeline and clinical milestones have caught the attention of both investors and analysts, shining a brighter light on its potential growth. New partnerships and progress on several promising drug candidates have added some fuel to the optimism, helping the stock to rebound from earlier lulls and notch an impressive 45.9% gain over the last five years. Of course, for serious investors, the question always comes back to valuation. By one popular scoring system, Neurocrine earns a v
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) CapsulesPR Newswire
- Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences to Present at Upcoming Investor ConferencesPR Newswire
NBIX
Earnings
- 10/28/25 - Beat
NBIX
Sec Filings
- 12/4/25 - Form 4
- 12/3/25 - Form 144
- 12/2/25 - Form 4
- NBIX's page on the SEC website